{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:05:51Z","timestamp":1792425951682,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04050-5","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T14:01:29Z","timestamp":1757426489000},"page":"746-756","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of ocular toxicity in patients with gynecologic cancer receiving novel antibody\u2013drug conjugates: a narrative review"],"prefix":"10.1007","volume":"28","author":[{"given":"Giuseppa","family":"Scandurra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Marano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Gebbia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Sambataro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0446-6436","authenticated-orcid":false,"given":"Valentina","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Angelico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Scollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Scibilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Pizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"4050_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"key":"4050_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.936","volume":"5","author":"A Mazidimoradi","year":"2022","unstructured":"Mazidimoradi A, Momenimovahed Z, Allahqoli L, Tiznobaik A, Hajinasab N, Salehiniya H, et al. The global, regional and national epidemiology, incidence, mortality, and burden of ovarian cancer. Health Sci Rep. 2022;5:e936. https:\/\/doi.org\/10.1002\/hsr2.936.","journal-title":"Health Sci Rep"},{"key":"4050_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","volume":"21","author":"PM Webb","year":"2024","unstructured":"Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024;21:389\u2013400. https:\/\/doi.org\/10.1038\/s41571-024-00881-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"4050_CR4","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.3390\/ijms25031845","volume":"25","author":"V Tavares","year":"2024","unstructured":"Tavares V, Marques IS, Melo IGD, Assis J, Pereira D, Medeiros R. Paradigm shift: a comprehensive review of ovarian cancer management in an era of advancements. IJMS. 2024;25:1845. https:\/\/doi.org\/10.3390\/ijms25031845.","journal-title":"IJMS."},{"key":"4050_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ygyno.2021.08.032","volume":"163","author":"S Gaillard","year":"2021","unstructured":"Gaillard S, Oaknin A, Ray-Coquard I, Vergote I, Scambia G, Colombo N, et al. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: a multicenter, randomized, controlled, open-label phase 3 study (CORAIL). Gynecol Oncol. 2021;163:237\u201345. https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.032.","journal-title":"Gynecol Oncol"},{"key":"4050_CR6","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1200\/JCO.21.00334","volume":"39","author":"J Hamanishi","year":"2021","unstructured":"Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA). J Clin Oncol. 2021;39:3671\u201381. https:\/\/doi.org\/10.1200\/JCO.21.00334.","journal-title":"J Clin Oncol"},{"key":"4050_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071663","volume":"13","author":"A Indini","year":"2021","unstructured":"Indini A, Nigro O, Lengyel CG, Ghidini M, Petrillo A, Lopez S, et al. Immune-checkpoint inhibitors in platinum-resistant ovarian cancer. Cancers (Basel). 2021;13:13:1663. https:\/\/doi.org\/10.3390\/cancers13071663.","journal-title":"Cancers (Basel)"},{"key":"4050_CR8","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. JCO. 2014;32:1302\u20138. https:\/\/doi.org\/10.1200\/JCO.2013.51.4489.","journal-title":"JCO"},{"key":"4050_CR9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/13543784.2023.2179483","volume":"32","author":"I Vergote","year":"2023","unstructured":"Vergote I, Ray-Coquard I, Lorusso D, Oaknin A, Cibula D, Van Gorp T. Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline? Expert Opin Investig Drugs. 2023;32:201\u201311. https:\/\/doi.org\/10.1080\/13543784.2023.2179483.","journal-title":"Expert Opin Investig Drugs"},{"key":"4050_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.101978","author":"J He","year":"2025","unstructured":"He J, Chen M, Jia L, Wang Y. Antibody-drug conjugates in gynecologic cancer: current landscape, clinical data, and emerging targets. Int J Gynecol Cancer. 2025. https:\/\/doi.org\/10.1016\/j.ijgc.2025.101978.","journal-title":"Int J Gynecol Cancer"},{"key":"4050_CR11","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.3390\/pharmaceutics15082017","volume":"15","author":"J Hurwitz","year":"2023","unstructured":"Hurwitz J, Haggstrom LR, Lim E. Antibody-drug conjugates: ushering in a new era of cancer therapy. Pharmaceutics. 2023;15:2017. https:\/\/doi.org\/10.3390\/pharmaceutics15082017.","journal-title":"Pharmaceutics"},{"key":"4050_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390772","author":"HC Karpel","year":"2023","unstructured":"Karpel HC, Powell SS, Pothuri B. Antibody-Drug Conjugates in Gynecologic Cancer. Am Soc Clin Oncol Educ Book. 2023. https:\/\/doi.org\/10.1200\/EDBK_390772.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"4050_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16142545","volume":"16","author":"S Sato","year":"2024","unstructured":"Sato S, Shoji T, Jo A, Otsuka H, Abe M, Tatsuki S, et al. Antibody-drug conjugates: the new treatment approaches for ovarian cancer. Cancers. 2024;16:2545. https:\/\/doi.org\/10.3390\/cancers16142545.","journal-title":"Cancers"},{"key":"4050_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102546","volume":"116","author":"A Tolcher","year":"2023","unstructured":"Tolcher A, Hamilton E, Coleman RL. The evolving landscape of antibody-drug conjugates in gynecologic cancers. Cancer Treat Rev. 2023;116:102546. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102546.","journal-title":"Cancer Treat Rev"},{"key":"4050_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115151","volume":"165","author":"OD Ogundipe","year":"2023","unstructured":"Ogundipe OD, Olajubutu O, Adesina SK. Targeted drug conjugate systems for ovarian cancer chemotherapy. Biomed Pharmacother. 2023;165:115151. https:\/\/doi.org\/10.1016\/j.biopha.2023.115151.","journal-title":"Biomed Pharmacother"},{"key":"4050_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/gco.0000000000000838","volume":"35","author":"J Tymon-Rosario","year":"2023","unstructured":"Tymon-Rosario J, Gorman M, Richardson DL, Washington C, Santin AD. Advances in antibody-drug conjugates for gynecologic malignancies. Curr Opin Obstet Gynecol. 2023;35:6\u201314. https:\/\/doi.org\/10.1097\/gco.0000000000000838.","journal-title":"Curr Opin Obstet Gynecol"},{"key":"4050_CR17","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1136\/ijgc-2022-003701","volume":"33","author":"A Chelariu-Raicu","year":"2023","unstructured":"Chelariu-Raicu A, Mahner S, Moore KN, Lorusso D, Coleman RL. Integrating antibody drug conjugates in the management of gynecologic cancers. Int J Gynecol Cancer. 2023;33:420\u20139. https:\/\/doi.org\/10.1136\/ijgc-2022-003701.","journal-title":"Int J Gynecol Cancer"},{"key":"4050_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1358\/dot.2022.58.5.3400745","volume":"58","author":"X Song","year":"2022","unstructured":"Song X, Li R, Wang H, Song P, Guo W, Chen Z-S. Tisotumab vedotin for the treatment of cervical carcinoma. Drugs Today. 2022;58:213\u201322. https:\/\/doi.org\/10.1358\/dot.2022.58.5.3400745.","journal-title":"Drugs Today"},{"key":"4050_CR19","unstructured":"MIRV BLA approval. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2022\/761310Orig1s000ltr.pdf."},{"key":"4050_CR20","unstructured":"TV BLA accelerated approval. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2021\/761208Orig1s000_Corrected_ltr.pdf."},{"key":"4050_CR21","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.22.01900","volume":"41","author":"UA Matulonis","year":"2023","unstructured":"Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J Clin Oncol. 2023;41:2436\u201345. https:\/\/doi.org\/10.1200\/JCO.22.01900.","journal-title":"J Clin Oncol"},{"key":"4050_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40265-023-01834-3","volume":"83","author":"Y-A Heo","year":"2023","unstructured":"Heo Y-A. Mirvetuximab soravtansine: first approval. Drugs. 2023;83:265\u201373. https:\/\/doi.org\/10.1007\/s40265-023-01834-3.","journal-title":"Drugs"},{"key":"4050_CR23","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1080\/14737140.2023.2236793","volume":"23","author":"RL Porter","year":"2023","unstructured":"Porter RL, Matulonis UA. Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer. Expert Rev Anticancer Ther. 2023;23:783\u201396. https:\/\/doi.org\/10.1080\/14737140.2023.2236793.","journal-title":"Expert Rev Anticancer Ther"},{"key":"4050_CR24","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1136\/ijgc-2024-005401","volume":"34","author":"RL Coleman","year":"2024","unstructured":"Coleman RL, Lorusso D, Oaknin A, Cecere SC, Denys H, Colombo N, et al. Mirvetuximab soravtansine in folate receptor alpha (FR\u03b1)\u2013high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial. Int J Gynecol Cancer. 2024;34:1119\u201325. https:\/\/doi.org\/10.1136\/ijgc-2024-005401.","journal-title":"Int J Gynecol Cancer"},{"key":"4050_CR25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","volume":"22","author":"RL Coleman","year":"2021","unstructured":"Coleman RL, Lorusso D, Gennigens C, Gonz\u00e1lez-Mart\u00edn A, Randall L, Cibula D, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:609\u201319. https:\/\/doi.org\/10.1016\/S1470-2045(21)00056-5.","journal-title":"Lancet Oncol"},{"key":"4050_CR26","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s40265-021-01633-8","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A. Tisotumab vedotin: first approval. Drugs. 2021;81:2141\u20137. https:\/\/doi.org\/10.1007\/s40265-021-01633-8.","journal-title":"Drugs"},{"key":"4050_CR27","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1007\/s12094-023-03261-y","volume":"25","author":"S Dom\u00ednguez-Llamas","year":"2023","unstructured":"Dom\u00ednguez-Llamas S, Caro-Magdaleno M, Mataix-Albert B, Avil\u00e9s-Prieto J, Romero-Barranca I, Rodr\u00edguez-de-la-R\u00faa E. Adverse events of antibody\u2013drug conjugates on the ocular surface in cancer therapy. Clin Transl Oncol. 2023;25:3086\u2013100. https:\/\/doi.org\/10.1007\/s12094-023-03261-y.","journal-title":"Clin Transl Oncol"},{"key":"4050_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.6004\/jadpro.2023.14.2.4","volume":"14","author":"R Arn","year":"2023","unstructured":"Arn R, Halla KJ, Gill S. Tisotumab vedotin safety and tolerability in clinical practice: managing adverse events. JADPRO. 2023;14:139\u201352. https:\/\/doi.org\/10.6004\/jadpro.2023.14.2.4.","journal-title":"JADPRO."},{"key":"4050_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1495137","volume":"15","author":"H Chen","year":"2024","unstructured":"Chen H, He G, Huang J, Hu L, Ma J. Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis. Front Immunol. 2024;15:1495137. https:\/\/doi.org\/10.3389\/fimmu.2024.1495137.","journal-title":"Front Immunol"},{"key":"4050_CR30","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","volume":"20","author":"JS De Bono","year":"2019","unstructured":"De Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels J-P, Arkenau H-T, et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20:383\u201393. https:\/\/doi.org\/10.1016\/S1470-2045(18)30859-3.","journal-title":"Lancet Oncol"},{"key":"4050_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2313811","volume":"391","author":"I Vergote","year":"2024","unstructured":"Vergote I, Gonz\u00e1lez-Mart\u00edn A, Fujiwara K, Kalbacher E, Bagam\u00e9ri A, Ghamande S, et al. Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. N Engl J Med. 2024;391:44\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2313811.","journal-title":"N Engl J Med"},{"key":"4050_CR32","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.annonc.2024.11.011","volume":"36","author":"A Alvarez Secord","year":"2025","unstructured":"Alvarez Secord A, Lewin SN, Murphy CG, Cecere SC, Barqu\u00edn A, G\u00e1lvez-Montosa F, et al. The efficacy and safety of mirvetuximab soravtansine in FR\u03b1-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II piccolo trial. Ann Oncol. 2025;36:321\u201330. https:\/\/doi.org\/10.1016\/j.annonc.2024.11.011.","journal-title":"Ann Oncol"},{"key":"4050_CR33","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","volume":"32","author":"KN Moore","year":"2021","unstructured":"Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021;32:757\u201365. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.017.","journal-title":"Ann Oncol"},{"key":"4050_CR34","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore KN, Angelergues A, Konecny GE, Garc\u00eda Y, Banerjee S, Lorusso D, et al. Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer. N Engl J Med. 2023;389:2162\u201374. https:\/\/doi.org\/10.1056\/NEJMoa2309169.","journal-title":"N Engl J Med"},{"key":"4050_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101148","volume":"46","author":"DL Richardson","year":"2023","unstructured":"Richardson DL. Ocular toxicity and mitigation strategies for antibody drug conjugates in gynecologic oncology. Gynecol Oncol Rep. 2023;46:101148. https:\/\/doi.org\/10.1016\/j.gore.2023.101148.","journal-title":"Gynecol Oncol Rep"},{"key":"4050_CR36","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/jnci\/djz035","volume":"111","author":"MJ Birrer","year":"2019","unstructured":"Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-drug conjugate-based therapeutics: state of the science. JNCI J Natl Cancer Inst. 2019;111:538\u201349. https:\/\/doi.org\/10.1093\/jnci\/djz035.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"4050_CR37","unstructured":"Narayana RVL, Gupta R. Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment. Oncogene. 2025 [cited 2025 July 3]. https:\/\/www.nature.com\/articles\/s41388-025-03448-3."},{"key":"4050_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11864-023-01166-0","volume":"25","author":"MK Anastasio","year":"2024","unstructured":"Anastasio MK, Shuey S, Davidson BA. Antibody-drug conjugates in gynecologic cancers. Curr Treat Options Oncol. 2024;25:1\u201319. https:\/\/doi.org\/10.1007\/s11864-023-01166-0.","journal-title":"Curr Treat Options Oncol"},{"key":"4050_CR39","doi-asserted-by":"publisher","first-page":"7088","DOI":"10.3390\/curroncol31110522","volume":"31","author":"S Fasih","year":"2024","unstructured":"Fasih S, Welch S, Lohmann AE. Antibody-drug conjugates: a start of a new era in gynecological cancers. Curr Oncol. 2024;31:7088\u2013106. https:\/\/doi.org\/10.3390\/curroncol31110522.","journal-title":"Curr Oncol"},{"key":"4050_CR40","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","volume":"8","author":"H Donaghy","year":"2016","unstructured":"Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs. 2016;8:659\u201371. https:\/\/doi.org\/10.1080\/19420862.2016.1156829.","journal-title":"MAbs"},{"key":"4050_CR41","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.2147\/CMAR.S294080","volume":"15","author":"V Agostinelli","year":"2023","unstructured":"Agostinelli V, Musacchio L, Camarda F, Salutari V, Carbone MV, Ghizzoni V, et al. Therapeutic potential of Tisotumab vedotin in the treatment of recurrent or metastatic cervical cancer: a short report on the emerging data. Cancer Manag Res. 2023;15:1063\u201372. https:\/\/doi.org\/10.2147\/CMAR.S294080.","journal-title":"Cancer Manag Res"},{"key":"4050_CR42","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","volume":"394","author":"CH Chau","year":"2019","unstructured":"Chau CH, Steeg PS, Figg WD. Antibody\u2013drug conjugates for cancer. Lancet. 2019;394:793\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(19)31774-X.","journal-title":"Lancet"},{"key":"4050_CR43","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1158\/1078-0432.CCR-18-2474","volume":"25","author":"UA Matulonis","year":"2019","unstructured":"Matulonis UA, Birrer MJ, O\u2019Malley DM, Moore KN, Konner J, Gilbert L, et al. Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody-drug conjugate Mirvetuximab Soravtansine. Clin Cancer Res. 2019;25:1727\u201336. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2474.","journal-title":"Clin Cancer Res"},{"key":"4050_CR44","doi-asserted-by":"publisher","DOI":"10.1177\/11795549231187264","author":"E Gonzalez-Ochoa","year":"2023","unstructured":"Gonzalez-Ochoa E, Veneziani AC, Oza AM. Mirvetuximab soravtansine in platinum-resistant ovarian cancer. Clin Med Insights Oncol. 2023. https:\/\/doi.org\/10.1177\/11795549231187264.","journal-title":"Clin Med Insights Oncol"},{"key":"4050_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0310736","volume":"19","author":"S Rehim","year":"2024","unstructured":"Rehim S, Yuan S, Wang H. Mirvetuximab soravtansine in solid tumors: a systematic review and meta-analysis. PLoS ONE. 2024;19:e0310736. https:\/\/doi.org\/10.1371\/journal.pone.0310736. (Lee C-HH, editor).","journal-title":"PLoS ONE"},{"key":"4050_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104230","volume":"194","author":"Y Wang","year":"2024","unstructured":"Wang Y, Liu L, Jin X, Yu Y. Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2024;194:104230. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104230.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4050_CR47","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/jco.2016.69.9538","volume":"35","author":"KN Moore","year":"2017","unstructured":"Moore KN, Martin LP, O\u2019Malley DM, Matulonis UA, Konner JA, Perez RP, et al. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody\u2013drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. JCO. 2017;35:1112\u20138. https:\/\/doi.org\/10.1200\/jco.2016.69.9538.","journal-title":"JCO"},{"key":"4050_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70392","author":"ET Kim","year":"2024","unstructured":"Kim ET, Kim JH, Park EY, Song IH, Park HS, Park S, et al. The efficacy and safety of folate receptor \u03b1-targeted antibody-drug conjugate therapy in patients with high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers: a systematic review and meta-analysis. Cancer Med. 2024. https:\/\/doi.org\/10.1002\/cam4.70392.","journal-title":"Cancer Med"},{"key":"4050_CR49","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241277647","author":"F Camarda","year":"2024","unstructured":"Camarda F, Paderno M, Cannizzaro MC, Nero C, Sabatucci I, Fuc\u00e0 G, et al. Antibody drug conjugates in recurrent or metastatic cervical cancer: a focus on tisotumab vedotin state of art. Ther Adv Med Oncol. 2024. https:\/\/doi.org\/10.1177\/17588359241277647.","journal-title":"Ther Adv Med Oncol."},{"key":"4050_CR50","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1177\/10600280221118370","volume":"57","author":"N Heitz","year":"2023","unstructured":"Heitz N, Greer SC, Halford Z. A review of Tisotumab vedotin-tftv in recurrent or metastatic cervical cancer. Ann Pharmacother. 2023;57:585\u201396. https:\/\/doi.org\/10.1177\/10600280221118370.","journal-title":"Ann Pharmacother"},{"key":"4050_CR51","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1200\/JCO.23.00720","volume":"41","author":"I Vergote","year":"2023","unstructured":"Vergote I, Van Nieuwenhuysen E, O\u2019Cearbhaill RE, Westermann A, Lorusso D, Ghamande S, et al. Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: results from the innovaTV 205\/GOG-3024\/ENGOT-cx8 study. JCO. 2023;41:5536\u201349. https:\/\/doi.org\/10.1200\/JCO.23.00720.","journal-title":"JCO"},{"key":"4050_CR52","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","volume":"31","author":"JS Eaton","year":"2015","unstructured":"Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther. 2015;31:589\u2013604. https:\/\/doi.org\/10.1089\/jop.2015.0064.","journal-title":"J Ocul Pharmacol Ther"},{"key":"4050_CR53","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1089\/jop.2023.0069","volume":"39","author":"M Jaffry","year":"2023","unstructured":"Jaffry M, Choudhry H, Aftab OM, Dastjerdi MH. Antibody-drug conjugates and ocular toxicity. J Ocul Pharmacol Ther. 2023;39:675\u201391. https:\/\/doi.org\/10.1089\/jop.2023.0069.","journal-title":"J Ocul Pharmacol Ther"},{"key":"4050_CR54","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ygyno.2017.08.015","volume":"147","author":"LP Martin","year":"2017","unstructured":"Martin LP, Konner JA, Moore KN, Seward SM, Matulonis UA, Perez RP, et al. Characterization of folate receptor alpha (FR\u03b1) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FR\u03b1-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017;147:402\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2017.08.015.","journal-title":"Gynecol Oncol"},{"key":"4050_CR55","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","volume":"170","author":"L Gilbert","year":"2023","unstructured":"Gilbert L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, Lim PC, Castro CM, et al. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2023;170:241\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2023.01.020.","journal-title":"Gynecol Oncol"},{"key":"4050_CR56","doi-asserted-by":"publisher","unstructured":"Moore K, O'Malley D, Vergote I, Martin L, Gonzalez-Martin A, Wang J, et al. 18\/#499\u2005Mirvetuximab soravtansine and carboplatin for treatment of patients with recurrent folate receptor alpha-positive platinum-sensitive ovarian cancer: a final analysis. Featured Printed Posters (Poster Rounds with the Professors). BMJ Publishing Group Ltd; 2022 [cited 2025 July 14]. p. A33.2\u2013A34. https:\/\/doi.org\/10.1136\/ijgc-2022-igcs.62.","DOI":"10.1136\/ijgc-2022-igcs.62"},{"key":"4050_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2023.101979","volume":"33","author":"AA Parikh","year":"2024","unstructured":"Parikh AA, Hanna J, Shah AP. Acute keratoconjunctivitis associated with tisotumab vedotin-tftv for metastatic cervical cancer. Am J Ophthalmol Case Rep. 2024;33:101979. https:\/\/doi.org\/10.1016\/j.ajoc.2023.101979.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"4050_CR58","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/bcp.16250","volume":"91","author":"Y Tu","year":"2025","unstructured":"Tu Y, Lagraauw HM, Method M, Wang Y, Hanze E, Li L, et al. Exposure\u2013response relationships of mirvetuximab soravtansine in patients with folate receptor-\u03b1-positive ovarian cancer: justification of therapeutic dose regimen. Brit J Clinical Pharma. 2025;91:220\u201331. https:\/\/doi.org\/10.1111\/bcp.16250.","journal-title":"Brit J Clinical Pharma"},{"key":"4050_CR59","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ygyno.2022.02.010","volume":"165","author":"SK Kim","year":"2022","unstructured":"Kim SK, Ursell P, Coleman RL, Monk BJ, Vergote I. Mitigation and management strategies for ocular events associated with tisotumab vedotin. Gynecol Oncol. 2022;165:385\u201392. https:\/\/doi.org\/10.1016\/j.ygyno.2022.02.010.","journal-title":"Gynecol Oncol"},{"key":"4050_CR60","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/ICU.0000000000001063","volume":"35","author":"RF Marshall","year":"2024","unstructured":"Marshall RF, Xu H, Berkenstock M. Ocular toxicities associated with antibody drug conjugates. Curr Opin Ophthalmol. 2024;35:494\u20138. https:\/\/doi.org\/10.1097\/ICU.0000000000001063.","journal-title":"Curr Opin Ophthalmol"},{"key":"4050_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1425617","volume":"15","author":"K Mao","year":"2024","unstructured":"Mao K, Chen P, Sun H, Zhong S, Zheng H, Xu L. Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS). Front Pharmacol. 2024;15:1425617. https:\/\/doi.org\/10.3389\/fphar.2024.1425617.","journal-title":"Front Pharmacol"},{"key":"4050_CR62","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/14740338.2023.2251380","volume":"22","author":"F Raheem","year":"2023","unstructured":"Raheem F, Alsuhebany N, Hickey Zacholski E, Paulic N, Sandler A, Uk N, et al. Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies. Expert Opin Drug Saf. 2023;22:921\u20138. https:\/\/doi.org\/10.1080\/14740338.2023.2251380.","journal-title":"Expert Opin Drug Saf"},{"key":"4050_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102867","volume":"134","author":"B Bouguerra Zina","year":"2025","unstructured":"Bouguerra Zina B, Rousseau F, Fauquier S, Sabatier R, Kfoury M. Practical clinical management of ocular adverse events related to antibody-drug conjugates in gynaecological malignancies. Cancer Treat Rev. 2025;134:102867. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102867.","journal-title":"Cancer Treat Rev"},{"key":"4050_CR64","doi-asserted-by":"publisher","first-page":"e1435","DOI":"10.1093\/oncolo\/oyae177","volume":"29","author":"GK Dy","year":"2024","unstructured":"Dy GK, Farooq AV, Kang JJ. Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies. Oncologist. 2024;29:e1435\u201351. https:\/\/doi.org\/10.1093\/oncolo\/oyae177.","journal-title":"Oncologist"},{"key":"4050_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030713","volume":"15","author":"TD Nguyen","year":"2023","unstructured":"Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers. 2023;15:713. https:\/\/doi.org\/10.3390\/cancers15030713.","journal-title":"Cancers"},{"key":"4050_CR66","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s40121-024-00990-7","volume":"13","author":"J Litt","year":"2024","unstructured":"Litt J, Cunningham AL, Arnalich-Montiel F, Parikh R. Herpes zoster ophthalmicus: presentation, complications, treatment, and prevention. Infect Dis Ther. 2024;13:1439\u201359. https:\/\/doi.org\/10.1007\/s40121-024-00990-7.","journal-title":"Infect Dis Ther"},{"key":"4050_CR67","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2167907","author":"D Curran","year":"2023","unstructured":"Curran D, Patterson BJ, Carrico J, Salem A, La EM, Lorenc S, et al. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer. Hum Vaccines Immunother. 2023. https:\/\/doi.org\/10.1080\/21645515.2023.2167907.","journal-title":"Hum Vaccines Immunother."},{"key":"4050_CR68","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/ICO.0000000000001805","volume":"38","author":"E Corbelli","year":"2019","unstructured":"Corbelli E, Miserocchi E, Marchese A, Giuffr\u00e8 C, Berchicci L, Sacconi R, et al. Ocular toxicity of mirvetuximab. Cornea. 2019;38:229\u201332. https:\/\/doi.org\/10.1097\/ICO.0000000000001805.","journal-title":"Cornea"},{"key":"4050_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101155","volume":"47","author":"A Hendershot","year":"2023","unstructured":"Hendershot A, Slabaugh M, Riaz KM, Moore KN, O\u2019Malley DM, Matulonis U, et al. Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine. Gynecol Oncol Rep. 2023;47:101155. https:\/\/doi.org\/10.1016\/j.gore.2023.101155.","journal-title":"Gynecol Oncol Rep"},{"key":"4050_CR70","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cncr.34507","volume":"129","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Liu K, Wang K, Zhu H. Treatment-related adverse events of antibody\u2013drug conjugates in clinical trials: a systematic review and meta-analysis. Cancer. 2023;129:283\u201395. https:\/\/doi.org\/10.1002\/cncr.34507.","journal-title":"Cancer"},{"key":"4050_CR71","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/APO.0000000000000331","volume":"9","author":"L Lim","year":"2020","unstructured":"Lim L, Lim EWL. Therapeutic contact lenses in the treatment of corneal and ocular surface diseases\u2014a review. Asia-Pac J Ophthalmol. 2020;9:524\u201332. https:\/\/doi.org\/10.1097\/APO.0000000000000331.","journal-title":"Asia-Pac J Ophthalmol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04050-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04050-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04050-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:19:19Z","timestamp":1771510759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04050-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":71,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["4050"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04050-5","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}